Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Xencor Inc (XNCR)  
$19.98 0.75 (3.9%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 66,383,000
Market Cap: 1.33(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $16.53 - $28.72
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 2
Insider 6 Months    : 2
Insider 3/6 Months : 4.3
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 53 53 53 53
Total Buy Value $1,013 $1,013 $1,013 $1,013
Total People Bought 1 1 1 1
Total Buy Transactions 1 1 1 1
Total Shares Sold 101,351 146,351 179,848 214,693
Total Sell Value $2,152,463 $3,094,133 $3,971,419 $5,040,525
Total People Sold 5 5 5 6
Total Sell Transactions 10 11 12 27
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 312
  Page 10 of 13  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Foster Paul A Chief Medical Officer   •       –      –    2016-08-03 4 AS $20.01 $100,050 D/D (5,000) 2,419     -
   Foster Paul A Chief Medical Officer   •       –      –    2016-08-03 4 OE $4.25 $21,250 D/D 5,000 7,419     -
   Desjarlais John R Sr. V.P., Research & CSO   •       –      –    2016-08-03 4 AS $20.00 $118,100 D/D (5,905) 44,934     -
   Baracchini Edgardo Jr Chief Business Officer   •       –      –    2016-08-03 4 AS $20.00 $90,560 D/D (4,528) 0     -
   Baracchini Edgardo Jr Chief Business Officer   •       –      –    2016-07-11 4 AS $18.13 $22,663 D/D (1,250) 4,528     -
   Baracchini Edgardo Jr Chief Business Officer   •       –      –    2016-07-11 4 OE $0.59 $738 D/D 1,250 5,778     -
   Foster Paul A Chief Medical Officer   •       –      –    2016-06-28 4 AS $17.01 $20,123 D/D (1,183) 2,419     -
   Baracchini Edgardo Jr Chief Business Officer   •       –      –    2016-06-28 4 AS $15.10 $18,875 D/D (1,250) 4,528     -
   Baracchini Edgardo Jr Chief Business Officer   •       –      –    2016-06-28 4 OE $0.59 $738 D/D 1,250 5,778     -
   Kuch John J Vice President, Finance   •       –      –    2016-06-24 4 OE $0.59 $29,500 D/D 50,000 77,728     -
   Dahiyat Bassil I President and CEO   •       •      –    2016-05-24 4 AS $13.00 $596,523 D/D (45,886) 312,300     -
   Dahiyat Bassil I President and CEO   •       •      –    2016-05-24 4 OE $0.59 $67,681 D/D 114,714 358,186     -
   Baracchini Edgardo Jr Chief Business Officer   •       –      –    2016-04-07 4 AS $15.00 $56,250 D/D (3,750) 4,528     -
   Baracchini Edgardo Jr Chief Business Officer   •       –      –    2016-04-07 4 OE $0.59 $2,213 D/D 3,750 8,278     -
   Dahiyat Bassil I President and CEO   •       •      –    2016-03-17 4 AS $11.02 $505,554 D/D (45,886) 243,472     -
   Dahiyat Bassil I President and CEO   •       •      –    2016-03-17 4 OE $0.59 $67,682 D/D 114,716 289,358     -
   Desjarlais John R Sr. V.P., Research & CSO   •       –      –    2016-03-03 4/A AS $12.00 $31,620 D/D (2,635) 50,697     -
   Desjarlais John R Sr. V.P., Research & CSO   •       –      –    2016-03-03 4/A OE $0.59 $4,064 D/D 6,888 53,332     -
   Desjarlais John R Sr. V.P., Research & CSO   •       –      –    2016-03-03 4 AS $12.00 $31,620 D/D (2,635) 50,337     -
   Desjarlais John R Sr. V.P., Research & CSO   •       –      –    2016-03-03 4 OE $0.59 $4,064 D/D 6,888 52,972     -
   Desjarlais John R Sr. V.P., Research & CSO   •       –      –    2016-03-02 4/A AS $12.01 $135,284 D/D (11,265) 46,444     -
   Desjarlais John R Sr. V.P., Research & CSO   •       –      –    2016-03-02 4 AS $12.01 $139,607 D/D (11,625) 46,084     -
   Desjarlais John R Sr. V.P., Research & CSO   •       –      –    2016-03-02 4 OE $0.59 $16,905 D/D 28,653 57,709     -
   Stafford John S Iii 10% Owner   –       –       •   2016-02-01 4 S $10.79 $270 I/I (25) 0     -
   Stafford John S Iii 10% Owner   –       –       •   2016-01-29 4 B $10.83 $271 I/I 25 25 1.42     -
  312 Records found
  Previous  10  11  12  13   
  Page 10 of 13
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us